Sonrotoclax
- Generic Name
- Sonrotoclax
Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 47
- Registration Number
- NCT06497062
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2025-05-11
- Target Recruit Count
- 30
- Registration Number
- NCT06463691
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-04-16
- Target Recruit Count
- 66
- Registration Number
- NCT06367374
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
- Conditions
- CLL
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 652
- Registration Number
- NCT06073821
- Locations
- 🇺🇸
Alaska Oncology and Hematology, Llc, Anchorage, Alaska, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of California San Diego (Ucsd) Moores Cancer Center, La Jolla, California, United States
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
- Conditions
- Waldenstrom's Macroglobulinemia RefractoryWaldenstrom's Macroglobulinemia RecurrentWaldenstrom Macroglobulinemia
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 105
- Registration Number
- NCT05952037
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Medstar Georgetown University Hospital, Washington, District of Columbia, United States
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- LeukemiaLymphomaRefractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaSmall Lymphocytic LymphomaRelapsed Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 100
- Registration Number
- NCT05479994
- Locations
- 🇨🇳
Hainan Cancer Hospital, Haikou, Hainan, China
🇨🇳The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
🇨🇳Nanyang Central Hospital, Nanyang, Henan, China
Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Mantle Cell LymphomaRefractory Mantle Cell Lymphoma (MCL)Relapsed Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 126
- Registration Number
- NCT05471843
- Locations
- 🇧🇷
Hospital Das Clinicas Da Faculdade de Medicina de Ribeirao Preto Usp, Ribeirao Preto, Brazil
🇧🇷Oncoclinicas Rio de Janeiro Sa, Rio de Janeiro, Brazil
🇬🇧Churchill Hospital Oxford University Hospital Nhs Trust, Headington, United Kingdom
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 167
- Registration Number
- NCT04973605
- Locations
- 🇺🇸
University of Alabama At Birmingham Hospital, Birmingham, Alabama, United States
🇧🇷Hospital Sirio Libanes Brasilia, Brasilia, Brazil
🇧🇷Instituto Dor de Pesquisa E Ensino Distrito Federal, Brasilia, Brazil
Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 64
- Registration Number
- NCT04883957
- Locations
- 🇨🇳
Peking University Peoples Hospital, Beijing, Beijing, China
🇨🇳Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi, China
A Study of BGB-11417 in Participants With Myeloid Malignancies
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasm
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 260
- Registration Number
- NCT04771130
- Locations
- 🇫🇷
Hopital Saint Louis, Paris, France
🇩🇪Universitaetsklinikum Leipzig Aor, Leipzig, Germany
🇩🇪Universitaetsklinikum Ulm, Ulm, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.